An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Clinical trial NCT01968109 · COMPLETED
Trial details
- NCT number
- NCT01968109
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-11-05
- Primary completion
- 2024-05-22
- Enrollment
- 1482
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.